Quarterly report pursuant to Section 13 or 15(d)

Unaudited Condensed Consolidated Statements of Operations

v3.21.2
Unaudited Condensed Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Operating expenses:    
Research and development $ 5,774 $ 2,344
General and administrative 1,866 1,279
Total operating expenses 7,640 3,623
Operating loss (7,640) (3,623)
Non-operating income (expense):    
Employee retention credit 231  
Gain on change in fair value of embedded derivative liability 16  
Interest expense, net (443) 3
Total non-operating income (expense), net (196) 3
Net loss $ (7,836) $ (3,620)
Net loss per common share - basic (in dollars per share) $ (0.92) $ (0.62)
Net loss per common share - diluted (in dollars per share) $ (0.92) $ (0.62)
Weighted average number of common shares outstanding - basic (in shares) 8,513 5,867
Weighted average number of common shares outstanding - diluted (in shares) 8,513 5,867